<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675723</url>
  </required_header>
  <id_info>
    <org_study_id>19-005227</org_study_id>
    <nct_id>NCT04675723</nct_id>
  </id_info>
  <brief_title>The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection</brief_title>
  <official_title>The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being done to identify types of bacteria associated with the lining of the large&#xD;
      intestine in people who have recently been treated for C. difficile infection to determine if&#xD;
      there are features associated with recurrent disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have recently been diagnosed with C. difficile infection and completed treatment&#xD;
      will be enrolled to undergo evaluation of the colonic mucosa via sigmoid biopsies.&#xD;
      Participants will also complete surveys, blood draw and stool collection. Overall goals are&#xD;
      to identify whether C. difficile is persisting in the colon mucosa after treated infection,&#xD;
      and whether this, and other clinical and microbiome factors may be playing a role in disease&#xD;
      recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal presence</measure>
    <time_frame>1-14 days post C. Difficile treatment</time_frame>
    <description>Identification of C. difficile within the colonic mucosa on stained slides from biopsy samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease recurrence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determination of recurrent C. difficile infection based on symptoms and potential clinical testing</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clostridioides Difficile Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients without known underlying inflammatory GI conditions with recent diagnosis and&#xD;
        treatment of C. difficile infection, for whom the recent diagnosis was not that of&#xD;
        recurrent disease already&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adults aged 18 and over&#xD;
&#xD;
          -  Confirmed C. difficile infection based on positive C. difficile toxin PCR testing and&#xD;
             clinical evidence of diarrhea&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Prior diagnosis of C. difficile infection within 2 months of this diagnosis&#xD;
&#xD;
          -  Other known active gastrointestinal infectious process&#xD;
&#xD;
          -  Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or&#xD;
             other inflammatory conditions&#xD;
&#xD;
          -  Vulnerable adults&#xD;
&#xD;
          -  Any other disease(s), condition(s) or habit(s) that would interfere with completion of&#xD;
             study, or in the judgment of the investigator would potentially interfere with&#xD;
             compliance to this study or would adversely affect study outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Purna Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Schupack, M.D.</last_name>
      <phone>507-284-4824</phone>
      <email>schupack.daniel@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lekatz</last_name>
      <phone>507-538-1206</phone>
      <email>lekatz.heather@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Purna C. Kashyap, MBBS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

